Altering cancer transcriptomes using epigenomic inhibitors

Epigenetics and Chromatin

Volumn 8, Issue 1, 2015, Pages

  Gaddis, Malaina ^a   Gerrard, Diana ^b   Frietze, Seth ^b   Farnham, Peggy J ^a  

^a UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^b UNIVERSITY OF NORTHERN COLORADO   (United States)

Author keywords

C646; Cholesterol biosynthesis; Colon cancer; Epigenetic inhibitor; Histone acetylation; ICG 001; Pancreatic cancer; TCF7L2; WNT signaling

Indexed keywords

ACETYL COENZYME A; ANTINEOPLASTIC AGENT; BETA CATENIN; C 646; CYCLIC AMP RESPONSIVE ELEMENT BINDING PROTEIN BINDING PROTEIN; E1A ASSOCIATED P300 PROTEIN; EPIGENETIC INHIBITOR; LIGAND; N BENZYL 1,2,3,4,8,9 HEXAHYDRO 6 (4 HYDROXYBENZYL) 8 (1 NAPHTHYLMETHYL) 4,7 DIOXO 2H PYRAZINO[1,2 A]PYRIMIDINE 1(6H) CARBOXAMIDE; RECEPTOR; T CELL FACTOR PROTEIN; TRANSCRIPTOME; UNCLASSIFIED DRUG;

ARTICLE; CANCER PATIENT; CARCINOGENICITY; CELL CYCLE; CELL DIFFERENTIATION; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; COMPLEX FORMATION; CONTROLLED STUDY; DOWN REGULATION; GENE ACTIVATION; GENE CONTROL; GENE EXPRESSION; GENETIC TRANSCRIPTION; GENOME; HCT116 CELL LINE; HISTONE ACETYLATION; HUMAN; HUMAN CELL; LIGAND BINDING; PANCREATIC CANCER CELL LINE; PRIORITY JOURNAL; PROTEIN BINDING; RECEPTOR BINDING; WNT SIGNALING PATHWAY;

EID: 84937147465     PISSN: None     EISSN: 17568935     Source Type: Journal    
DOI: 10.1186/1756-8935-8-9     Document Type: Article

References (49)

1. Luu HH, Zhang R, Haydon RC, Rayburn E, Kang Q, Si W, et al.: Wnt/beta-catenin signaling pathway as a novel cancer drug target. Curr Cancer Drug Targets. 2004, 4: 653-71. 10.2174/1568009043332709
2. Polakis P: Wnt signaling in cancer. Cold Spring Harb Perspect Biol. 2012, 4: a008052.
3. Takahashi-Yanaga F, Kahn M: Targeting Wnt signaling: can we safely eradicate cancer stem cells? Clin Cancer Res. 2010, 16: 3153-62. 10.1158/1078-0432.CCR-09-2943
4. Tian W, Han X, Yan M, Xu Y, Duggineni S, Lin N, et al.: Structure-based discovery of a novel inhibitor targeting the beta-Catenin/Tcf4 interaction. Biochemistry. 2012, 51: 724-31. 10.1021/bi201428h
5. Calo E, Wysocka J: Modification of enhancer chromatin: what, how, and why? Mol Cell. 2013, 49: 825-37. 10.1016/j.molcel.2013.01.038
6. Portela A, Esteller M: Epigenetic modifications and human disease. Nat Biotechnol. 2010, 28: 1057-68. 10.1038/nbt.1685
7. Clevers H: Wnt/beta-catenin signaling in development and disease. Cell. 2006, 127: 469-80. 10.1016/j.cell.2006.10.018
8. Shitashige M, Hirohashi S, Yamada T: Wnt signaling inside the nucleus. Cancer Sci. 2008, 99: 631-7. 10.1111/j.1349-7006.2007.00716.x
9. Eguchi M, Nguyen C, Lee SC, Kahn M: ICG-001, a novel small molecule regulator of TCF/beta-catenin transcription. Med Chem. 2005, 1: 467-72. 10.2174/1573406054864098
10. Emami KH, Nguyen C, Ma H, Kim DH, Jeong KW, Eguchi M, et al.: A small molecule inhibitor of beta-catenin/CREB-binding protein transcription [corrected]. Proc Natl Acad Sci U S A. 2004, 101: 12682-7. 10.1073/pnas.0404875101
11. Bowers EM, Yan G, Mukherjee C, Orry A, Wang L, Holbert MA, et al.: Virtual ligand screening of the p300/CBP histone acetyltransferase: identification of a selective small molecule inhibitor. Chem Biol. 2010, 17: 471-82. 10.1016/j.chembiol.2010.03.006
12. Miki T, Yasuda SY, Kahn M: Wnt/beta-catenin signaling in embryonic stem cell self-renewal and somatic cell reprogramming. Stem Cell Rev. 2011, 7: 836-46. 10.1007/s12015-011-9275-1
13. Rebel VI, Kung AL, Tanner EA, Yang H, Bronson RT, Livingston DM: Distinct roles for CREB-binding protein and p300 in hematopoietic stem cell self-renewal. Proc Natl Acad Sci U S A. 2002, 99: 14789-94. 10.1073/pnas.232568499
14. Ugai H, Uchida K, Kawasaki H, Yokoyama KK: The coactivators p300 and CBP have different functions during the differentiation of F9 cells. J Mol Med (Berl). 1999, 77: 481-94. 10.1007/s001099900021
15. Teo JL, Kahn M: The Wnt signaling pathway in cellular proliferation and differentiation: a tale of two coactivators. Adv Drug Deliv Rev. 2010, 62: 1149-55. 10.1016/j.addr.2010.09.012
16. Kalkhoven E: CBP and p300: HATs for different occasions. Biochem Pharmacol. 2004, 68: 1145-55. 10.1016/j.bcp.2004.03.045
17. Ramos YF, Hestand MS, Verlaan M, Krabbendam E, Ariyurek Y, van Galen M, et al.: Genome-wide assessment of differential roles for p300 and CBP in transcription regulation. Nucleic Acids Res. 2010, 38: 5396-408. 10.1093/nar/gkq184
18. Foley P, Bunyan D, Stratton J, Dillon M, Lynch SA: Further case of Rubinstein-Taybi syndrome due to a deletion in EP300. Am J Med Genet A. 2009, 149A: 997-1000. 10.1002/ajmg.a.32771
19. Ma H, Nguyen C, Lee KS, Kahn M: Differential roles for the coactivators CBP and p300 on TCF/beta-catenin-mediated survivin gene expression. Oncogene. 2005, 24: 3619-31. 10.1038/sj.onc.1208433
20. Morris JP, Wang SC, Hebrok M: KRAS, Hedgehog, Wnt and the twisted developmental biology of pancreatic ductal adenocarcinoma. Nat Rev Cancer. 2010, 10: 683-95. 10.1038/nrc2899
21. Zavoral M, Minarikova P, Zavada F, Salek C, Minarik M: Molecular biology of pancreatic cancer. World J Gastroenterol. 2011, 17: 2897-908. 10.3748/wjg.v17.i24.2897
22. Zhang Y, Morris JP, Yan W, Schofield HK, Gurney A, Simeone DM, et al.: Canonical wnt signaling is required for pancreatic carcinogenesis. Cancer Res. 2013, 73: 4909-22. 10.1158/0008-5472.CAN-12-4384
23. Nakamoto M, Matsuyama A, Shiba E, Shibuya R, Kasai T, Yamaguchi K, et al.: Prognostic significance of WNT signaling in pancreatic ductal adenocarcinoma. Virchows Arch. 2014, 465: 401-8. 10.1007/s00428-014-1642-2
24. Wall I, Schmidt-Wolf IG: Effect of Wnt inhibitors in pancreatic cancer. Anticancer Res. 2014, 34: 5375-80.
25. Xu W, Wang Z, Zhang W, Qian K, Li H, Kong D, et al.: Mutated K-ras activates CDK8 to stimulate the epithelial-to-mesenchymal transition in pancreatic cancer in part via the Wnt/beta-catenin signaling pathway. Cancer Lett. 2015, 356: 613-27. 10.1016/j.canlet.2014.10.008
26. Jia J, Parikh H, Xiao W, Hoskins JW, Pflicke H, Liu X, et al.: An integrated transcriptome and epigenome analysis identifies a novel candidate gene for pancreatic cancer. BMC Med Genomics. 2013, 6: 33. 10.1186/1755-8794-6-33
27. Dekker FJ, Haisma HJ: Histone acetyl transferases as emerging drug targets. Drug Discov Today. 2009, 14: 942-8. 10.1016/j.drudis.2009.06.008
28. Geutjes EJ, Bajpe PK, Bernards R: Targeting the epigenome for treatment of cancer. Oncogene. 2012, 31: 3827-44. 10.1038/onc.2011.552
29. Helin K, Dhanak D: Chromatin proteins and modifications as drug targets. Nature. 2013, 502: 480-8. 10.1038/nature12751
30. Wang L, Tang Y, Cole PA, Marmorstein R: Structure and chemistry of the p300/CBP and Rtt109 histone acetyltransferases: implications for histone acetyltransferase evolution and function. Curr Opin Struct Biol. 2008, 18: 741-7. 10.1016/j.sbi.2008.09.004
31. Gorin A, Gabitova L, Astsaturov I: Regulation of cholesterol biosynthesis and cancer signaling. Curr Opin Pharmacol. 2012, 12: 710-6. 10.1016/j.coph.2012.06.011
32. Gabitova L, Gorin A, Astsaturov I: Molecular pathways: sterols and receptor signaling in cancer. Clin Cancer Res. 2014, 20: 28-34. 10.1158/1078-0432.CCR-13-0122
33. Brown MS, Goldstein JL: The SREBP pathway: regulation of cholesterol metabolism by proteolysis of a membrane-bound transcription factor. Cell. 1997, 89: 331-40. 10.1016/S0092-8674(00)80213-5
34. Shimano H: Sterol regulatory element-binding proteins (SREBPs): transcriptional regulators of lipid synthetic genes. Prog Lipid Res. 2001, 40: 439-52. 10.1016/S0163-7827(01)00010-8
35. Xiao X, Song BL: SREBP: a novel therapeutic target. Acta Biochim Biophys Sin (Shanghai). 2013, 45: 2-10. 10.1093/abbs/gms112
36. Oliner JD, Andresen JM, Hansen SK, Zhou S, Tjian R: SREBP transcriptional activity is mediated through an interaction with the CREB-binding protein. Genes Dev. 1996, 10: 2903-11. 10.1101/gad.10.22.2903
37. Arensman MD, Telesca D, Lay AR, Kershaw KM, Wu N, Donahue TR, et al.: The CREB-binding protein inhibitor ICG-001 suppresses pancreatic cancer growth. Mol Cancer Ther. 2014, 13: 2303-14. 10.1158/1535-7163.MCT-13-1005
38. Ciliberto D, Botta C, Correale P, Rossi M, Caraglia M, Tassone P, et al.: Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials. Eur J Cancer. 2013, 49: 593-603. 10.1016/j.ejca.2012.08.019
39. Giroux V, Malicet C, Barthet M, Gironella M, Archange C, Dagorn JC, et al.: p8 is a new target of gemcitabine in pancreatic cancer cells. Clin Cancer Res. 2006, 12: 235-41. 10.1158/1078-0432.CCR-05-1700
40. Hamidi T, Algul H, Cano CE, Sandi MJ, Molejon MI, Riemann M, et al.: Nuclear protein 1 promotes pancreatic cancer development and protects cells from stress by inhibiting apoptosis. J Clin Invest. 2012, 122: 2092-103. 10.1172/JCI60144
41. Sandi MJ, Hamidi T, Malicet C, Cano C, Loncle C, Pierres A, et al.: p8 expression controls pancreatic cancer cell migration, invasion, adhesion, and tumorigenesis. J Cell Physiol. 2011, 226: 3442-51. 10.1002/jcp.22702
42. Clark DW, Mitra A, Fillmore RA, Jiang WG, Samant RS, Fodstad O, et al.: NUPR1 interacts with p53, transcriptionally regulates p21 and rescues breast epithelial cells from doxorubicin-induced genotoxic stress. Curr Cancer Drug Targets. 2008, 8: 421-30. 10.2174/156800908785133196
43. Koster R, di Pietro A, Timmer-Bosscha H, Gibcus JH, van den Berg A, Suurmeijer AJ, et al.: Cytoplasmic p21 expression levels determine cisplatin resistance in human testicular cancer. J Clin Invest. 2010, 120: 3594-605. 10.1172/JCI41939
44. Vincent AJ, Ren S, Harris LG, Devine DJ, Samant RS, Fodstad O, et al.: Cytoplasmic translocation of p21 mediates NUPR1-induced chemoresistance: NUPR1 and p21 in chemoresistance. FEBS Lett. 2012, 586: 3429-34. 10.1016/j.febslet.2012.07.063
45. Weiss RH: p21Waf1/Cip1 as a therapeutic target in breast and other cancers. Cancer Cell. 2003, 4: 425-9. 10.1016/S1535-6108(03)00308-8
46. Chen D, Niu M, Jiao X, Zhang K, Liang J, Zhang D: Inhibition of AKT2 enhances sensitivity to gemcitabine via regulating PUMA and NF-kappaB signaling pathway in human pancreatic ductal adenocarcinoma. Int J Mol Sci. 2012, 13: 1186-208. 10.3390/ijms13011186
47. Mu GG, Zhang LL, Li HY, Liao Y, Yu HG: Thymoquinone pretreatment overcomes the insensitivity and potentiates the antitumor effect of gemcitabine through abrogation of notch1, PI3K/Akt/mTOR regulated signaling pathways in pancreatic cancer. Dig Dis Sci 2014. doi:10.1007/s10620-014-3394-x
48. Anders S, Pyl PT, Huber W: HTSeq-a Python framework to work with high-throughput sequencing data. Bioinformatics. 2015, 31: 166-9. 10.1093/bioinformatics/btu638
49. Robinson MD, McCarthy DJ, Smyth GK: edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics. 2010, 26: 139-40. 10.1093/bioinformatics/btp616